Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts MLYS Hot Sheet
Join SI Premium – FREE
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($2.85), $0.22 worse than the analyst estimate of ($2.63).
For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Downgrades Thyssenkrupp Nucera AG (NCH2:GR) to Hold
- Morgan Stanley Downgrades Smith & Nephew PLC. (SN:LN) (SNN) to Equalweight
- MongoDB (MDB) Reiterated at Market Outperform by Citizens as Guidance Exceeds Estimate
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
